In a premenopausal, receptor positive node positive woman with breast cancer who has regular menses prior to initiation of chemotherapy and then stops during chemotherapy, how do you determine the timing of ovarian suppression or treatment with medication or oophorectomy?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

Related Questions

How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?

How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?

How would you treat a patient with T1c HR-, HER2+ breast cancer, stage IV, with involvement of multiple bilateral axillary nodes and no evidence of distant metastasis?

In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?

In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?

How would you approach a postmenopausal patient on Letrozole who developed cataracts within the first six months of treatment?

Is there a role for adjuvant pembrolizumab/capecitabine in a patient with TNBC who receives neoadjuvant AC-T with residual disease found at time of surgery?

As a clinician, what are the management differences between lobular and ductal carcinoma of the breast?

In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?

Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?